Movement Alert｜Sanofi SA rises 3.01% in Pre-Market Trading, Q3 Dupixent sales jump 34.8%

Market Focus10-30

On October 30, Sanofi SA rose 3.01% in Pre-Market Trading, trading at $44.78 per share, with turnover of $323.2 thousand.

The move followed the company’s latest quarterly update, with third-quarter Dupixent sales reaching €5.7 billion, up 34.8% year over year, while vaccines sales were €3.2 billion, down 6.6%.

The market appeared to focus on the strong growth of Dupixent, a key product for Sanofi SA, especially as prior expectations had been relatively cautious on revenue and earnings. Earlier in October, the company also signed a letter of intent with the pan-Canadian Pharmaceutical Alliance covering Dupixent in four additional indications, adding support to expectations for further volume expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment